49 results about "Minocycline" patented technology

The invention relates to an isopentenyl-alpha-pyrone dimer Hyperumonates D-F as well as a preparation method and application thereof, and belongs to the field of medical chemistry, the isopentenyl-alpha-pyrone dimer Hyperumonates D-F is obtained by extracting and separating from leaves and branches of Hypericum monogynum for the first time, and the structural formula of the isopentenyl-alpha-pyrone dimer Hyperumonates D-F is D-F. The invention further discloses a preparation method of the isopentenyl-alpha-pyrone dimer Hyperumonates D-F. The isopentenyl-alpha-pyrone dimer Hypericumonates D-F has the advantages that the compounds D-E have remarkable inhibition effects on generation of NO in mouse microglial cells (BV-2 cells) induced by lipopolysaccharide (LPS), the activity of the compounds D-E is higher than that of positive medicine minocycline, and the compounds D-E have application potentials in the field of neuroinflammation medicines, and the invention also relates to a pharmaceutical composition which comprises the isopentenyl-alpha-pyrone dimer Hypericumonates D-F and can be used for preparing medicines for treating neuroinflammation. And pharmaceutically acceptable auxiliary materials, wherein the pharmaceutical composition has the effect of resisting neuroinflammation.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

The application belongs to the technical field of medicine, and relates to a use of minocycline in preparation of an antitumor synergist. The minocycline, as the antitumor synergist, has a synergistic effect with 5-fluorouracil and gemcitabine, significantly enhances the curative effect of an antitumor drug, reduces the dosage of the antitumor drug, and reduces side effects of the antitumor drug on the body or damage of the antitumor drug to normal tissue cells.

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

The invention belongs to the technical field of medicines, and relates to application of minocycline in preparation of an anti-tumor synergist. The minocycline is used as an anti-tumor synergist and has a synergistic effect with the 5-fluorouracil and the gemcitabine, so that the curative effect of the anti-tumor medicine is remarkably enhanced, the dosage of the anti-tumor medicine is reduced, and the body side effect caused by the anti-tumor medicine or the damage to normal tissue cells is reduced.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially / fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

The present invention discloses a strain of Acinetobacter spp. LDH6-2 and its application in degrading tetracycline antibiotics. The LDH6-2 strain was deposited in Guangdong Province Microbial Culture Collection Center on November 23, 2023, with a deposit number of GDMCC NO: 64034. The Acinetobacter spp. LDH6-2 of the present invention is different from other reported strains at the genomic level. It is a new type of Acinetobacter species, which has tetracycline antibiotic degradation ability and can significantly degrade tetracycline, minocycline and tigecycline within 24 h, and the degradation rate of the newly listed eravacycline reaches (75.8 ± 2.9)%, and has good application prospects in the degradation of residual tetracycline antibiotics in water and soil environments.

The invention discloses an AcrB efflux pump inhibitor with a membrane permeabilization effect as well as a preparation method and application thereof. The AcrB efflux pump inhibitor is a solvent compound, an enantiomer, a diastereoisomer, a tautomer or a mixture of a compound with a structure as shown in a formula I or pharmaceutically acceptable salt of the compound, wherein R is C6-C16 straight chain or branched chain alkyl, alkenyl, ester group, amide or substituted phenyl; x is N or C; y is N or C. The compound provided by the invention has better efflux inhibition activity, and the minimum inhibitory concentration can be reduced by 64 times when the compound is combined with minocycline for use.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano-micelle preparation loaded with minocycline and application of the nano-micelle preparation to treatment of cerebral hemorrhage, the nano-micelle preparation is prepared by taking a polyethylene glycol-polycaprolactone nano material PEG3000-PCL2000 as a carrier, and jointly loading minocycline MINO and a CD147 monoclonal antibody Anti-CD147, so that the nano-micelle preparation is prepared. And the bionic nano-drug MINO (at) PNM (at) CD147 with an active targeting function is constructed. The nano-micelle preparation has a brain targeting property and can be enriched in cerebral hemorrhage tissues, so that the local drug concentration and the treatment efficiency are remarkably improved; the traditional Chinese medicine composition can improve neurological impairment caused by cerebral hemorrhage and significantly reduce the volume of cerebral hematoma, and has an obvious treatment effect on cerebral hemorrhage; the number of inflammatory cells in the peripheral area of hematoma and expression of inflammatory mediators can be remarkably reduced, and therefore the inflammatory response in cerebral hemorrhage tissue is relieved.

The present invention relates to the technical field of traditional Chinese medicine, and in particular to an antibacterial Chinese medicine composition and its application. The Chinese medicine composition of the present invention includes 1-10 parts of sappan wood extract, 1-3 parts of sanguisorba officinalis charcoal extract, 1-10 parts of rose extract, 1-5 parts of blood-seeing shrew extract, 1-5 parts of madder charcoal extract, 1-5 parts of hawthorn extract, and 1-5 parts of stir-fried tribulus extract. The Chinese medicine composition has a very significant inhibitory effect on Acinetobacter baumannii, and can play a synergistic effect with antibiotics such as imipenem and minocycline, significantly improving the therapeutic effect of Acinetobacter baumannii infection.

The invention discloses injectable hydrogel for treating periodontitis as well as a preparation method and application of the injectable hydrogel. The injectable hydrogel is prepared from the following raw materials: chitosan and derivatives thereof, oxidative modified natural polysaccharide and modified hydroxyapatite, the modified hydroxyapatite comprises hydroxyapatite, and the surface of the hydroxyapatite is modified with a metal polyphenol network. The modified hydroxyapatite has multiple functions of oxidation resistance, immunoregulation, osteogenesis promotion, migration promotion, tube formation promotion, antibiosis and the like, and can be combined with the injectable hydrogel with biological adhesion and self-healing performance to realize better in-vivo tissue healing. The injectable hydrogel of the composite functional hydroxyapatite nanoparticles synthesized by the invention has biocompatibility, oxidation resistance, immunoregulation performance, osteogenesis promotion performance and antibacterial performance, and can realize better alveolar bone regeneration and repair in a rat periodontitis model, and the effect of the injectable hydrogel is superior to that of clinically common minocycline.

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

The invention provides a flexible neural electrode composite coating and a preparation method and application thereof, the flexible neural electrode composite coating comprises polycaprolactone containing an anti-inflammatory drug minocycline and a nanofiber of methacrylated silk fibroin, the surface of the nanofiber is modified with a conductive polymer poly (3, 4-ethylenedioxythiophene) in situ, and the conductive polymer poly (3, 4-ethylenedioxythiophene) is modified with a conductive polymer poly (3, 4-ethylenedioxythiophene). Cured methacrylated silk fibroin hydrogel is formed on the surface of the modified material. According to the composite coating, the electrochemical performance is remarkably improved, the inflammatory reaction is relieved, and the biocompatibility is improved through the hydrogel. The composite coating has high charge storage / injection capacity, low interface impedance and good biocompatibility, and can stably record bio-electricity signals for a long time. The invention provides the invasive flexible neural electrode composite coating with remarkable anti-inflammatory action, excellent electrochemical performance and long-term stability, and reliable technical support is provided for clinical application of neural electrodes.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

To provide a method for treating Community-Acquired Bacterial Pneumonia (CABP).SOLUTION: A method comprises administering, to a subject, 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline or a salt thereof according to a following dosing regimen: (1) three intravenous doses of about 100 mg each, which are administered every 12 hours; (2) subsequent optional one or more intravenous doses of about 100 mg each, each of which is administered 24 hours after the immediate preceding intravenous dose; (3) subsequent optional one oral dose of about 300 mg, which is administered in the morning and 12-24 hours after the immediate preceding intravenous dose; and (4) subsequent optional one or more oral doses of about 300 mg each, each of which is administered 24 hours after the immediate preceding oral dose.SELECTED DRAWING: Figure 1

To provide methods for treating bacterial infection of skin or skin structure.SOLUTION: Provided is a method for treating bacterial infection of skin or skin structure in a human subject in need thereof, the method comprising a step of orally administering to the subject 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline or a salt thereof at a dose of about 450 mg per day for consecutive two days, then at a dose of about 300 mg per day for five days or longer.SELECTED DRAWING: None

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition. 21504026_1 (GHMatters) P114073.AU.1 20 25 20 08 26 06 F eb 2 02 5 A B S T R A C T 2 0 2 5 2 0 0 8 2 6 0 6 F e b 2 0 2 5

A strategy for bacterial persister control using amphiphilic antibiotics that do not require active transport to penetrate bacterial membranes of persister cells. Persister cells have reduced drug efflux and accumulate more minocycline than normal cells, leading to effective killing of this dormant subpopulation upon wake-up. While dormancy is a well-known cause of antibiotic tolerance, it also provides an Achilles' heel for controlling persister cells by leveraging dormancy associated reduction of drug efflux.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

Methods and compositions for treating bacterial infections using tetracycline compounds are described. For example, in one embodiment, the invention provides a method for treating an infected subject, comprising administering an effective amount of 9-[(2,2-dimethylpropylamino)-methyl]-minocycline or a salt thereof to said subject to treat said subject, wherein 9-[(2,2-dimethylpropylamino)-methyl]-minocycline is orally administered for two consecutive days at a dose of about 450 mg / day, followed by administration for five or more days at a dose of about 300 mg / day.

The present invention relates to a composition for preventing or treating periodontal disease and a dental composite antibiotic ointment composition. The composition for preventing or treating periodontal disease according to the present invention comprises minocycline and metronidazole as effective ingredients.

The invention discloses an alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C as well as a preparation method and application of the alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C, and belongs to the technical field of medical chemistry. The alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C has a structure as shown in formulas A-C, and the alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C is obtained by being separated from Hypericum monogynum for the first time. The alpha-pyrone mixed source meroterpenoid dimer Hypericumonates A-C has a structure as shown in formulas A-C; the compound Hypericumonates A-C has obvious inhibitory activity on NO concentration in BV-2 cells induced by lipopolysaccharide (LPS), shows an obvious anti-inflammatory effect, has the activity higher than that of a positive control drug minocycline, can inhibit expression of iNOS and COX-2 in a dose-dependent manner, and can be applied to preparation of anti-neuroinflammation drugs.

The application is suitable for the technical field of drug synthesis, and provides a continuous flow preparation method and system of a secondary amine derivative of C9 position of omadacycline, the method is that minocycline C9-amino methylate, alkyl aldehyde compound and tertiary amine acid acceptor are dissolved in an organic solvent to form a raw material liquid, hydrogen is continuously introduced into a microreactor filled with a solid palladium carbon catalyst, and a reductive amination reaction is carried out under the condition of 50-70 DEG C and 1.0-2.5 MPa, the residence time of the material is 10-30 minutes, and high-purity product is obtained after post-treatment. The special system includes a feeding module, a mixing and preheating module, a microreaction module, a detection and control module and a product collection module, and each module cooperates to realize continuous and high-precision reaction. The application solves the defects of low efficiency, high safety risk and unstable product quality of the traditional kettle process, the product yield is more than 95%, the HPLC purity is higher than 98.5%, and the application is intrinsically safe, easy to industrialize, and environmentally friendly.

Compositions and methods are provided for using DispersinB® and a second antimicrobial which does not comprise a bacteriophage or transglutaminase enzyme as a topical anti-acne treatment. The second antimicrobial may be selected from the group consisting of organic peroxide, benzoyl peroxide, tetracyclines such as minocycline and doxycycline, macrolides such as erythromycin and azithromycin, and clindamycin.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention relates to the technical field of medicines, in particular to a tannic acid / Cu < 2 + > / minocycline compound and application thereof. The preparation method of the compound comprises the following steps: complexing tannic acid (TA) and Cu < 2 + >, and loading minocycline (MH) by taking the complex as a carrier. The TA-Cu / MH prepared by the preparation method disclosed by the invention has multiple effects of resisting bacteria, resisting oxidation, resisting inflammation and the like, and also has good safety and a certain effect of promoting tissue regeneration. The research provides an experimental basis for application of a multifunctional drug in periodontitis treatment, and is beneficial to promoting precise drug treatment of periodontitis.

The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.